Company / Operating Margin
Intellia Therapeutics, Inc. Operating Margin History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-651.7%
FY2025
5-year range
-1420.5% / -651.7%
FY2021-FY2025
Trend
+29.4%
vs FY2024
Sector context
#140 of 143
Health Care
What the data says
Among 143 Health Care companies, Intellia Therapeutics, Inc. is in the bottom 2% for operating margin. Improved from -1420.5% to -651.7% over the past 2 years.
Based on SEC 10-K filings.
-651.7% in FY2025 with a 5-year CAGR of -416.2%.
Improved from -1420.5% to -651.7% over the past 2 years.
Health Care sector context is included.
Operating Margin over time
Growth rates
- 3-Year Change
- +227.4pp
- 5-Year Change
- -416.2pp
- 10-Year Change
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 143This company -651.7% Sector average -295.2%
▼
-120.7% below sector average
Key checks
Key Insights
- In FY2025, operating margin increased 29.4% year-over-year.
- Currently 356.4pp below the Health Care sector average.
- Peak operating margin was recorded in FY2020.
- Lowest operating margin in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.14 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -651.7% | +29.4% |
| FY2024 | -923.1% | +35.0% |
| FY2023 | -1420.5% | -61.6% |
| FY2022 | -879.0% | -8.5% |
| FY2021 | -810.4% | -244.1% |
| FY2020 | -235.5% | +4.6% |
| FY2019 | -246.8% | +17.3% |
| FY2018 | -298.6% | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026